Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$5.53 USD
-0.27 (-4.66%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.49 -0.04 (-0.72%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Recursion Pharmaceuticals, Inc.'s return on equity, or ROE, is -74.70% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that RXRX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
RXRX 5.53 -0.27(-4.66%)
Will RXRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Other News for RXRX
Decoding Recursion Pharmaceuticals Inc (RXRX): A Strategic SWOT Insight
Recursion Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $19. ...
Recursion Sets $100 Million Partnership Goal by 202
Recursion Pharmaceuticals (RXRX) Exceeds Revenue Expectations in Q2
Recursion Pharmaceuticals (RXRX) Reports Mixed Q2 Results with Revenue Beat